|Title:||Sustained release pharmaceutical compounds to prevent abuse of controlled substances|
|Abstract:||The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.|
|Inventor(s):||Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Lauderback; Christopher (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA)|
|Assignee:||Shire LLC (Florence, KY)|
|Filing Date:||Aug 23, 2004|
|Claims:||1. A pharmaceutical composition comprising: codeine; and a carrier covalently bound to the codeine in a manner that renders the codeine pharmacologically inactive or provides reduced pharmacological activity compared to codeine alone when administered parenterally, but provides pharmacologically effective amounts of codeine when administered orally; wherein the carrier is a peptide selected from the group consisting of Gly-Gly-Leu, Gly-Gly-Glu, Gly-Gly-Ile, Gly-Gly-Phe, Gly-Leu-Ile, Gly-Phe-Ile, Gly-Leu-Leu, Gly-Phe-Leu, Leu-Pro-Glu, Leu-Pro-Leu, Leu-Pro-Phe, Pro-Pro-Glu, Pro-Pro-Leu, Pro-Pro-Ile, Pro-Pro-Phe, Glu-Glu-Glu, Leu-Leu-Glu, Leu-Leu-Leu, Gly.sub.4-Leu (SEQ ID NO: 1), Glu.sub.5 (SEQ ID NO: 2), Gly.sub.4-Ile (SEQ ID NO: 3), Gly.sub.4-Phe (SEQ ID NO: 5), Glu.sub.2-Gly.sub.2 (SEQ ID NO: 6), Glu.sub.2-Gly.sub.2-Leu (SEQ ID NO: 8), or Glu2-Gly2-Ile (SEQ ID NO: 9); wherein the hydroxyl group of codeine is bound to the C-terminus of the carrier. |
2. The composition of claim 1, wherein said composition is in tablet, a capsule, an oral suspension or an oral solution.